2186:HKEXLuye Pharma Group Ltd. Analysis

Luye Pharma is trading at HK$1.96, which sits just above its 20‑day SMA (HK$1.90) but remains well below the 50‑day (HK$2.17) and 200‑day (HK$2.76) averages, indicating a short‑term bounce within a longer‑term bearish backdrop. The 14‑day RSI of 47.9 suggests neutral momentum, while the MACD line has crossed above its signal, generating a bullish histogram signal that could support a modest upside. Volatility is elevated at 71% 30‑day, yet the stock’s beta of 0.53 points to lower systematic risk compared with the market. The company’s PE of 14x is roughly half the industry average of 29.6x, and a forward PE of 7.3x underscores earnings acceleration expectations. A DCF‑derived fair value of HK$4.33 implies an upside of nearly 80% from current levels. Despite a modest revenue growth of 4.7%, margins remain healthy (gross 66%, operating 19%), though free cash flow is negative and ROE sits at only 4.1%. The balance sheet shows a debt‑to‑equity of 56% with cash holdings (HK$7.5 bn) exceeding debt (HK$10.3 bn) only partially, leaving a net debt position. No dividend is paid, and the payout ratio is zero. Overall, the stock appears deeply discounted relative to peers, but the combination of high volatility, modest profitability, and a sizable drawdown history tempers the upside potential.